Agenda

Day 1: July 24, 2024
9:00 AM – 4:30 PM

9:00 AM	Welcome and Introduction
	Keynote
	NIH Common Fund/CFDE Resources
	Break (15 Min)
	Panel Discussion on How Data Policy (Privacy and Ethics) Impacts Historically Underserved Communities
	Workshop Breakout Session on Community Engagement Strategies These will be interactive sessions where attendees will have the opportunity to break out into small groups to address a series of questions. Virtual attendees will be able to participate in the discussion in virtual break out rooms.
	Lunch
	Panel Discussion on Data Use and Accessibility
	Break (15 Min)
	Workshop Breakout Session on Data Challenges and Barriers to Data Use These will be interactive sessions where attendees will have the opportunity to break out into small groups to address a series of questions. Virtual attendees will be able to participate in the discussion in virtual break out rooms.
	Closing Remarks
4:30 PM	Adjourn Day 1

Welcome and Opening Remarks
9:00 AM	NINDS Welcome Walter J. Koroshetz, MD Director, National Institute of Neurological Disorders and Stroke
9:10 AM	Engaging the Lived Experience Perspective on PD Therapeutics Rebekah Corlew, PhD Lived Experience Engagement Strategist, National Institute of Neurological Disorders and Stroke
Keynote Address: Landscape of PD Therapeutics Development
9:20 AM	Workshop Co-Chairs Welcome and Goals for the 2 Days Alice Chen-Plotkin, MD Parker Family Professor of Neurology, University of Pennsylvania Bill Martin, PhD Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine
10:00 AM	Break (5 minutes)
Session 1: PD Heterogeneity Moderator: Karl Kieburtz, MD, MPH, Professor, University of Rochester
10:05 AM	Motor Heterogeneity in Parkinson’s Disease: Challenges to Therapeutic Developments Anthony Lang, MD, FRCPC Director, Edmond J Safra Program in Parkinson’s Disease, University of Toronto
10:20 AM	Heterogeneity of Non-Motor Symptoms across Lewy Body Diseases Kathleen Poston, MD, MS, Edward F. and Irene Thiele Pimley Professor in Neurology and Neurological Sciences, Director, Stanford Movement Disorders Center, Stanford University
10:35 AM	Q & A Discussion (30 minutes)
11:05 AM	Break (10 minutes)
Session 2: Target Validation Moderator: Alice Chen-Plotkin, MD, Parker Family Professor of Neurology, University of Pennsylvania
11:15 AM	Evolving Arcs toward Disease-Modifying Therapy for Parkinson’s Michael Schwarzschild, MD, PhD Professor of Neurology, Massachusetts General Hospital, Harvard Medical School
11:30 AM	Targeting LRRK2: Why, Who, Where and When Mark R. Cookson, PhD National Institute on Aging
11:45 AM	An Industry Perspective on Target Validation For Neurologic Diseases David Stone, PhD VP, Head of Genetics and Target Identification, Cerevel Therapeutics, LLC
12:00 PM	Q & A Discussion (30 minutes)
12:30 PM	Lunch (60 minutes)
Session 3: Appropriate Tools to Enable Therapeutics Development Moderator: Shalini Padmanabhan, PhD, Vice President, Discovery & Translational Research, Michael J. Fox Foundation
1:30 PM	Teeing Up a Discussion about Appropriate Tools to Enable Therapeutics Development Patrik Brundin, MD, PhD Distinguished Scientist/Therapeutic Area Leader for Movement Disorders, Roche
1:45 PM	Preclinical Tools to Advance Parkinson Disease Therapeutics: What They Can and Cannot Do Laura Volpicelli-Daley, PhD Associate Professor, University of Alabama at Birmingham
2:00 PM	Q & A Discussion (30 minutes)
2:30 PM	Break (10 minutes)
Session 4: Biomarker Use Moderator: Danielle Graham, PhD, Head of Fluid Biomarkers and Bioanalysis, Biogen
2:40 PM	AI-Enabled Biomarkers: A Window into Parkinson’s Progression, Detection, and Treatment Response Dina Katabi, PhD Thuan and Nicole Pham Professor, Massachusetts Institute of Technology
2:55 PM	Identification of Proteomic Targets and Biomarkers: The Mapping Proteomics to Parkinson’s Disease Project (MAP2PD) Laura Winchester, DPhil Research Fellow, University of Oxford
3:10 PM	Understanding Biomarker Parameters to Enable Clinical Trials in Parkinson’s Disease Danielle Graham, PhD Head of Fluid Biomarkers and Bioanalysis, Biogen
3:25 PM	Q & A Discussion (30 minutes)
3:55 PM	Break (15 minutes)
Breakout Session Day 1
4:10 PM	Parallel Breakout Session What is missing that is holding back therapeutics development?
4:55 PM	Break (5 minutes)
End of Day 1
5:00 PM	Day 1 Wrap-up
5:10 PM	Adjourn for the day

Day 2: July 25, 2024
9:00 AM – 12:30 PM

9:00 AM	Panel Discussion on Training & Education Needs of the Data Community
	Two Concurrent Breakout Sessions These will be interactive sessions where attendees will have the opportunity to break out into small groups to address a series of questions. Virtual attendees will be able to participate in the discussion in virtual break out rooms. Workshop Breakout on Data Solutions to identified barriers from Day 1 Workshop Breakout to discuss the immediate Training Needs and Supports of the Community
	Break (10 Min)
	Workshop Closing Presentation & Wrap Up
12:30 PM	Adjourn Day 2

Agenda

Day 1: July 24, 20249:00 AM – 4:30 PM

Day 2: July 25, 20249:00 AM – 12:30 PM

Day 1: July 24, 2024
9:00 AM – 4:30 PM

Day 2: July 25, 2024
9:00 AM – 12:30 PM